CRA-US-001: Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management (PLATINUM

About this Study

The purpose of this research is to see if a drug, called patiromer, already approved by the U.S Food and Drug Administration (FDA), can help lower potassium while patients are in the emergency department.

Sponsor Protocol ID:CRA-US-001
IRB Number:UMMC-IRB-2022-244
Actively Enrolling
Phase 4
October 11, 2022
Eligibility Criteria
18 years old
Both Male and Female

Inclusion Criteria
  • Written informed consent
  • At least 18 years of age
  • Hyperkalemia, potassium greater than or equal to 5.8

Exclusion Criteria
  • Clinically significant arrhythmia
  • Patients who are hemodynamically unstable
  • Hyperkalemia solely due to overdose on potassium supplements
  • Known bowel obstruction
  • Currently being treated with or having taken potassium binders in the 7 days prior to baseline
  • Expected to receive dialysis during the first 6 hours of the study treatment period
  • Known hypersensitivity to patiromer or its ingredients
  • Participation in any other investigational device or drug study less than 30 days prior to screening, or current treatment with other investigational agent(s)
  • Known to be pregnant or breastfeeding

Categories Click category to view its trials.
Emergency Medicine
Participating Locations
Emergency Room (Children) - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Tamara Brock
Phone Number: 601-984-5581
Principal Investigator:Nandi, Utsav, M.D.
How to participate in our Clinical Trials